News /
min read /
February 3, 2024

Big Health names mental health equity expert and clinical psychologist, Dr. Juliette McClendon, Director of Medical Affairs


Dr. McClendon will lead the medical affairs function with a focus on increasing the reach of Big Health’s mental health solutions.

Dr. McClendon will lead the medical affairs function with focus on increasing the reach of Big Health’s mental health solutions

San Francisco, May 3rd, 2021 — Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced the appointment of Juliette McClendon, Ph.D., as Director of Medical Affairs with a focus on communicating the clinical value of Big Health’s solutions to clients and the public, advancing mental health equity, and expanding the reach of Big Health’s evidence-based mental health solutions.

McClendon is a clinical psychologist with expertise in the research and treatment of mood, anxiety and personality disorders. She is a nationally-known expert on racial and ethnic health disparities and has worked extensively to address the impact of stress and trauma on the mental and physical health of people of color. Prior to joining Big Health, McClendon served as an Assistant Professor of Psychiatry at Boston University School of Medicine and a psychologist at the National Center for PTSD in the Women’s Health Sciences Division of the Veteran’s Affairs (VA) Boston Healthcare System.

“Juliette is a clinical leader and recognized authority on mental health disparities and racial inequities,” said Jenna Carl, Ph.D., Vice President of Clinical Development and Medical Affairs at Big Health. “Her insights into improving relevance, engagement, and closing treatment gaps among underserved populations will be crucial as we put in place strategies to better support these communities.”

“My role at Big Health offers me the opportunity to have a rapid, large-scale impact on the mental health of individuals and to advance the company’s commitment to bringing millions back to good mental health,” said McClendon. “I join Big Health in its commitment to expanding treatment options and improving outcomes with affordable, accessible, and culturally relevant mental health solutions.”  

In 2020, McClendon was honored as a Health Disparities Research Institute Scholar by the National Institutes of Health (NIH). McClendon holds an undergraduate degree in psychology from Harvard University and a master’s and Ph.D. from Washington University in St. Louis in Clinical Psychology, with a focus on racial and ethnic health disparities.

On May 4th, Dr. McClendon will be speaking about the inequity in mental health care at the Business Group on Health’s Annual Conference alongside Peter Hames, Big Health’s CEO and Co-Founder, and Jae Kuller, Delta Air Line’s General Manager of Global Health and Wellbeing.

About Big Health

Big Health’s purpose is to help millions back to good mental health, with digital therapeutics that feature highly personalized behavioral programs for mental health. Big Health’s products are Sleepio™ for helping individuals address poor sleep; and Daylight™ for helping individuals address worry and anxiety. Designed by leading clinical experts, Big Health’s solutions feature evidence-based cognitive and behavioral techniques and are backed by more than 26 peer-reviewed research studies including 13 randomized controlled trials (RCTs). With offices in London and San Francisco, Big Health’s products are used by large multinational employers and major health plans to help improve sleep and mental health, covering millions of employee lives.

For media inquiries, please contact

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023